These data complementarily showed the promising antitumor effects of DR17 in prostate cancer in vitro and in vivo preclinical models by simultaneously targeting both the PI3K/AKT/mTOR pathway and the AR axis. This evidence concerns the gene MTOR and prostate cancer.